학술논문
The effect of chronic administration of safranal on systolic blood pressure in rats.
Document Type
Academic Journal
Author
Imenshahidi M; Pharmaceutical Research Center, Department of Pharmacodynamy and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.; Razavi BM; Targeted Drug Delivery Research Center, Department of Pharmacodynamy and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.; Faal A; School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.; Gholampoor A; School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.; Mousavi SM; School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.; Hosseinzadeh H; Pharmaceutical Research Center, Department of Pharmacodynamy and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Source
Publisher: Brieflands Country of Publication: Netherlands NLM ID: 101208407 Publication Model: Print Cited Medium: Print ISSN: 1735-0328 (Print) Linking ISSN: 17266882 NLM ISO Abbreviation: Iran J Pharm Res Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
1735-0328
Abstract
Safranal, the main component of Crocus sativus essential oil, exhibits different pharmacological activities. In this study, the effects of safranal, on blood pressure of normotensive and desoxycorticosterone acetate (DOCA) - salt induced hypertensive rats in chronic administration were investigated. Three doses of safranal (1, 2 and 4 mg/Kg/day) and spironolactone (50 mg/Kg/day) were administrated to the different groups of normotensive and hypertensive rats (at the end of 4 weeks treatment by DOCA-salt) for Five weeks. Then the effects of safranal on mean systolic blood pressure (MSBP) and heart rate (HR) were evaluated using tail cuff method. The duration of effect of safranal on SBP, was also evaluated. Our results indicated that chronic administration of safranal could reduce the MSBP in DOCA salt treated rats in a dose dependent manner. Safranal did not decrease the MSBP in normotensive rats. The data also showed that antihypertensive effects of safranal did not persist. In summary, our results showed that safranal exhibits antihypertensive and normalizing effect on BP in chronic administration.